Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma.

Ma Q, Long W, Xing C, Chu J, Luo M, Wang HY, Liu Q, Wang RF.

Front Immunol. 2018 Dec 21;9:2924. doi: 10.3389/fimmu.2018.02924. eCollection 2018. Review.

2.

Extracellular Vesicles As Modulators of Tumor Microenvironment and Disease Progression in Glioma.

Mondal A, Kumari Singh D, Panda S, Shiras A.

Front Oncol. 2017 Jul 5;7:144. doi: 10.3389/fonc.2017.00144. eCollection 2017. Review.

3.

The cancer stem cell niche(s): the crosstalk between glioma stem cells and their microenvironment.

Filatova A, Acker T, Garvalov BK.

Biochim Biophys Acta. 2013 Feb;1830(2):2496-508. doi: 10.1016/j.bbagen.2012.10.008. Epub 2012 Oct 16.

PMID:
23079585
4.

Immune microenvironment of gliomas.

Gieryng A, Pszczolkowska D, Walentynowicz KA, Rajan WD, Kaminska B.

Lab Invest. 2017 May;97(5):498-518. doi: 10.1038/labinvest.2017.19. Epub 2017 Mar 13. Review.

5.

Glioma Stem Cells: Signaling, Microenvironment, and Therapy.

Liebelt BD, Shingu T, Zhou X, Ren J, Shin SA, Hu J.

Stem Cells Int. 2016;2016:7849890. doi: 10.1155/2016/7849890. Epub 2016 Jan 6. Review.

6.

Novel function of MDA-9/Syntenin (SDCBP) as a regulator of survival and stemness in glioma stem cells.

Talukdar S, Das SK, Pradhan AK, Emdad L, Shen XN, Windle JJ, Sarkar D, Fisher PB.

Oncotarget. 2016 Aug 23;7(34):54102-54119. doi: 10.18632/oncotarget.10851.

7.

Targeting glioma stem cells: enough to terminate gliomagenesis?

Dong J, Huang Q.

Chin Med J (Engl). 2011 Sep;124(17):2756-63. Review.

PMID:
22040437
8.

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.

Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS.

J Neurosurg. 2013 Dec;119(6):1415-23. doi: 10.3171/2013.7.JNS1323. Epub 2013 Oct 4.

9.

Glioma Stem Cells and Their Microenvironments: Providers of Challenging Therapeutic Targets.

Codrici E, Enciu AM, Popescu ID, Mihai S, Tanase C.

Stem Cells Int. 2016;2016:5728438. doi: 10.1155/2016/5728438. Epub 2016 Feb 10. Review.

10.

The Impact of the Tumor Microenvironment on the Properties of Glioma Stem-Like Cells.

Audia A, Conroy S, Glass R, Bhat KPL.

Front Oncol. 2017 Jul 10;7:143. doi: 10.3389/fonc.2017.00143. eCollection 2017. Review.

11.

Tumor vasculature and glioma stem cells: Contributions to glioma progression.

Jhaveri N, Chen TC, Hofman FM.

Cancer Lett. 2016 Oct 1;380(2):545-51. doi: 10.1016/j.canlet.2014.12.028. Epub 2014 Dec 16. Review.

PMID:
25527451
12.

Stem cell-derived exosomes: roles in stromal remodeling, tumor progression, and cancer immunotherapy.

Fatima F, Nawaz M.

Chin J Cancer. 2015 Sep 14;34(12):541-53. doi: 10.1186/s40880-015-0051-5. Review.

13.

A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, suppresses stemness in glioma stem-like cells.

Kim RK, Kim MJ, Yoon CH, Lim EJ, Yoo KC, Lee GH, Kim YH, Kim H, Jin YB, Lee YJ, Cho CG, Oh YS, Gye MC, Suh Y, Lee SJ.

Mol Pharmacol. 2012 Sep;82(3):400-7. doi: 10.1124/mol.112.078402. Epub 2012 May 30.

PMID:
22648970
14.

Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy.

Friedman GK, Raborn J, Kelly VM, Cassady KA, Markert JM, Gillespie GY.

Front Oncol. 2013 Feb 28;3:28. doi: 10.3389/fonc.2013.00028. eCollection 2013.

15.

The novel long non-coding RNA TALNEC2, regulates tumor cell growth and the stemness and radiation response of glioma stem cells.

Brodie S, Lee HK, Jiang W, Cazacu S, Xiang C, Poisson LM, Datta I, Kalkanis S, Ginsberg D, Brodie C.

Oncotarget. 2017 May 9;8(19):31785-31801. doi: 10.18632/oncotarget.15991.

16.
17.

Microenvironmental clues for glioma immunotherapy.

Platten M, Ochs K, Lemke D, Opitz C, Wick W.

Curr Neurol Neurosci Rep. 2014 Apr;14(4):440. doi: 10.1007/s11910-014-0440-1. Review.

PMID:
24604058
18.

HIF1α regulates single differentiated glioma cell dedifferentiation to stem-like cell phenotypes with high tumorigenic potential under hypoxia.

Wang P, Lan C, Xiong S, Zhao X, Shan Y, Hu R, Wan W, Yu S, Liao B, Li G, Wang J, Zou D, Chen B, Feng H, Wu N.

Oncotarget. 2017 Apr 25;8(17):28074-28092. doi: 10.18632/oncotarget.15888.

19.

Cancer stem cells in glioblastoma--molecular signaling and therapeutic targeting.

Huang Z, Cheng L, Guryanova OA, Wu Q, Bao S.

Protein Cell. 2010 Jul;1(7):638-55. doi: 10.1007/s13238-010-0078-y. Epub 2010 Jul 29. Review.

20.

Immunosuppressive cells in tumor immune escape and metastasis.

Liu Y, Cao X.

J Mol Med (Berl). 2016 May;94(5):509-22. doi: 10.1007/s00109-015-1376-x. Epub 2015 Dec 22. Review.

PMID:
26689709

Supplemental Content

Support Center